NCT02296294View on ClinicalTrials.gov

Body Composition Monitoring for Determination of the Fluid Status in Volunteers Undergoing Intravenous Fluid Therapy

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Fluid ShiftsBody Fluid Compartments
Interventions
DRUG

Elo-mel® (Fresenius Kabi Austria)

an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.

DEVICE

Body Composition Monitoring

BCM measurements every 10 minutes for 6 hours.

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT02296294 - Body Composition Monitoring for Determination of the Fluid Status in Volunteers Undergoing Intravenous Fluid Therapy | Biotech Hunter | Biotech Hunter